TGFB1 and hepatocellular carcinoma: A similar molecular pattern found in an HCC patient would suggest that TGF-β inhibitors may be considered in combination with other therapeutic approaches, since they would not induce any effect on tumor cells but could be beneficial in inhibiting the protumorigenic function of TGF-β in the tumor microenvironment.